- Home
- CELC vs PRME Comparison
CELC vs PRME Comparison
Compare CELC & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- PRME
- Stock Information
- Founded
- CELC 2011
- PRME 2019
- Country
- CELC United States
- PRME United States
- Employees
- CELC N/A
- PRME N/A
- Industry
- CELC Medical Specialities
- PRME Medicinal Chemicals and Botanical Products
- Sector
- CELC Health Care
- PRME Health Care
- Exchange
- CELC Nasdaq
- PRME Nasdaq
- Market Cap
- CELC 327.3M
- PRME N/A
- IPO Year
- CELC 2017
- PRME 2022
- Fundamental
- Price
- CELC $10.53
- PRME $1.34
- Analyst Decision
- CELC Strong Buy
- PRME Strong Buy
- Analyst Count
- CELC 6
- PRME 6
- Target Price
- CELC $30.17
- PRME $13.17
- AVG Volume (30 Days)
- CELC 195.9K
- PRME 1.5M
- Earning Date
- CELC 05-14-2025
- PRME 05-08-2025
- Dividend Yield
- CELC N/A
- PRME N/A
- EPS Growth
- CELC N/A
- PRME N/A
- EPS
- CELC N/A
- PRME N/A
- Revenue
- CELC N/A
- PRME $3,846,000.00
- Revenue This Year
- CELC N/A
- PRME $56.92
- Revenue Next Year
- CELC N/A
- PRME $150.59
- P/E Ratio
- CELC N/A
- PRME N/A
- Revenue Growth
- CELC N/A
- PRME 550.76
- 52 Week Low
- CELC $7.58
- PRME $1.12
- 52 Week High
- CELC $19.77
- PRME $8.27
- Technical
- Relative Strength Index (RSI)
- CELC 51.41
- PRME 40.43
- Support Level
- CELC $9.64
- PRME $1.30
- Resistance Level
- CELC $11.66
- PRME $1.83
- Average True Range (ATR)
- CELC 0.66
- PRME 0.19
- MACD
- CELC -0.04
- PRME -0.00
- Stochastic Oscillator
- CELC 44.06
- PRME 25.61
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.